PhIII implosion forces Galapagos to scrap a filing plan for filgotinib
Galapagos is blocking off one more development path for filgotinib, its JAK inhibitor with a checkered history, in the wake of a negative Phase III readout.
The drug — which is approved in Europe and Japan for other conditions as Jyseleca — failed one of two co-primary endpoints in a trial for Crohn’s disease, missing the bar on clinical remission and endoscopic response as an induction treatment. While it did hit the other co-primary endpoint as a maintenance therapy, Galapagos said it will not file for marketing authorization in Europe based on the topline data.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,400+ biopharma pros reading Endpoints daily — and it's free.